ErrorOKFree Rate QuoteCall now 623-889-0130 ErrorOK Although Franz thinks the Cardinals gave up too much for Kolb, he does admire the vigor with which the Cardinals approached their quarterback situation.“I wouldn’t have given up that much, but I applaud the aggression.”On the other side of the debate, Sports 620 KTAR’s Ron Wolfley supports the trade and does not appear to have the same reservations as Franz.“I feel good about it,” Wolfley said on Doug and Wolf. “This is a quarterback centric league and the Cards did not have a quarterback last year. Dominique Rodgers-Cromartie was on the team last year and they went 5-11.”Although the Cardinals had to acquire a quarterback, Wolfley admitted there are no guarantees in life and that this trade, and finding a franchise quarterback, is a total “crap shoot.”The Cardinals and their fans will have to wait and see how Kolb performs on the field, but right now the emotions and reactions are certainly mixed. Top Stories What an MLB source said about the D-backs’ trade haul for Greinke D-backs president Derrick Hall: Franchise ‘still focused on Arizona’ Comments Share Nevada officials reach out to D-backs on potential relocation Cardinals expect improving Murphy to contribute right away Kevin Kolb is finally a Cardinal, but the discussion does not end.The acquisition of Kolb has shifted the debate from who the Cardinals should get at quarterback to did they pay too much for a signal caller.“I think they paid too much and I know it doesn’t matter,” Sports 620 KTAR’s Doug Franz said on Doug and Wolf. “Either this trade works out and no one will ever care, or it’s going to be Kolb’s a joke and it doesn’t really matter how much you gave up.”
The announcement on Tuesday that Amazon, JPMorgan Chase and Berkshire Hathaway would be joining forces to create a health care company moved stock markets and prompted optimistic predictions of major reform in a notoriously complex industry. But while the three companies bring successful management, technological expertise and substantial capital to the venture, many health industry experts expressed doubts about whether their results would match their ambition. (Margot Sanger-Katz and Reed Abelson, 1/30) The New York Times: Can Amazon And Friends Handle Health Care? There’s Reason For Doubt Bloomberg: Amazon/Berkshire/JPMorgan Health Venture: Incumbents Should Fear Los Angeles Times: Universal Coverage, Courtesy Of The Corporate World? It’s Possible The great and oft-heralded Amazon.com Inc. foray into health care is here, and it’s not what we expected. The company isn’t diving headlong into drug distribution or becoming a pharmacy benefit manager (PBM). Along with JPMorgan Chase & Co. and Berkshire Hathaway Inc., it announced a more interesting idea Tuesday — a new company aimed at lowering the cost of employee health coverage. Though no one sector will face the full wrath of Bezos, this joint venture is a potential competitive threat to all of health care’s many middlemen. (Max Nisen, 1/30) Bloomberg: Can Amazon Transform Health Care? It’s Not A Crazy Idea Took ’em long enough. After decades of government leaders fumbling efforts to introduce some rational thinking to the over $3-trillion U.S. healthcare system, the corporate world has finally stepped in with an initiative that, in the best of all possible worlds, could provide a breakthrough that shows the way to universal coverage. (David Lazarus, 1/30) While the initial focus will be on technology, and the efforts will initially be aimed only at employees of the three firms, one suspects that the ambitions are slightly bigger: building a business that can somehow tamp down the pressures that drive health-care costs ever upward. In remaking the market for health-care services, they might even divert some small fraction of that gross national spending into their own pockets. (Megan McArdle, 1/30) Different Takes: Will Amazon’s Venture Be A Breakthrough In Lowering Healthcare Costs? Editorial pages feature writings on the new initiative between Amazon, JP Morgan and Berkshire Hathaway Inc. Bloomberg: JPMorgan Health Venture Poses A Hazard To Its Deal Fees The disruptive venture creates a conflict that may be hard to ignore for key executives at companies like UnitedHealth Group Inc., Humana Inc. and Express Scripts Holding Co., who may ice out JPMorgan’s bankers when it comes to seeking future transaction or capital markets advice. After all, why pad the profits of a firm whose actions have the ability to potentially shave billions of dollars from respective market values? (Gillian Tan, 1/30) This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.